Interpace Biosciences, Inc. (IDXG)
USD 1.18
(-8.01%)
USD 1.18
(-8.01%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 802 Thousand USD | 113.67% |
| 2022 | -5.86 Million USD | 60.23% |
| 2021 | -14.74 Million USD | 43.72% |
| 2020 | -26.2 Million USD | 1.64% |
| 2019 | -26.63 Million USD | -118.55% |
| 2018 | -12.18 Million USD | 0.22% |
| 2017 | -12.21 Million USD | -46.62% |
| 2016 | -8.33 Million USD | 26.63% |
| 2015 | -11.35 Million USD | 29.35% |
| 2014 | -16.07 Million USD | -252.09% |
| 2013 | -4.56 Million USD | 82.12% |
| 2012 | -25.52 Million USD | -114.26% |
| 2011 | -11.91 Million USD | -74.85% |
| 2010 | -6.81 Million USD | 79.7% |
| 2009 | -33.56 Million USD | 2.61% |
| 2008 | -34.46 Million USD | -245.51% |
| 2007 | -9.97 Million USD | -184.46% |
| 2006 | 11.8 Million USD | 160.7% |
| 2005 | -19.45 Million USD | -192.06% |
| 2004 | 21.13 Million USD | 72.39% |
| 2003 | 12.25 Million USD | 139.85% |
| 2002 | -30.76 Million USD | -584.12% |
| 2001 | 6.35 Million USD | -76.49% |
| 2000 | 27.02 Million USD | 159.88% |
| 1999 | 10.4 Million USD | 9.47% |
| 1998 | 9.5 Million USD | 326.19% |
| 1997 | -4.2 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 468 Thousand USD | -47.42% |
| 2024 Q2 | 2.06 Million USD | 340.6% |
| 2024 Q3 | 1.28 Million USD | -37.92% |
| 2023 Q4 | 890 Thousand USD | 244.95% |
| 2023 Q2 | 175 Thousand USD | -50.14% |
| 2023 Q3 | -614 Thousand USD | -450.86% |
| 2023 Q1 | 351 Thousand USD | 124.95% |
| 2023 FY | 802 Thousand USD | 113.67% |
| 2022 Q4 | -1.4 Million USD | -12.2% |
| 2022 FY | -5.86 Million USD | 60.23% |
| 2022 Q1 | -2.19 Million USD | 41.19% |
| 2022 Q2 | -3.88 Million USD | -77.25% |
| 2022 Q3 | -1.25 Million USD | 67.74% |
| 2021 Q1 | -4.2 Million USD | 48.34% |
| 2021 FY | -14.74 Million USD | 43.72% |
| 2021 Q3 | -3.56 Million USD | -3.34% |
| 2021 Q2 | -3.44 Million USD | 18.09% |
| 2021 Q4 | -3.72 Million USD | -4.72% |
| 2020 Q2 | -5.49 Million USD | 12.25% |
| 2020 Q4 | -8.14 Million USD | -30.62% |
| 2020 Q3 | -6.23 Million USD | -13.43% |
| 2020 Q1 | -6.26 Million USD | 41.6% |
| 2020 FY | -26.2 Million USD | 1.64% |
| 2019 FY | -26.63 Million USD | -118.55% |
| 2019 Q1 | -3.41 Million USD | 15.31% |
| 2019 Q2 | -5.22 Million USD | -52.68% |
| 2019 Q3 | -7.36 Million USD | -41.03% |
| 2019 Q4 | -10.72 Million USD | -45.68% |
| 2018 Q2 | -1.91 Million USD | 39.96% |
| 2018 FY | -12.18 Million USD | 0.22% |
| 2018 Q4 | -4.03 Million USD | -32.71% |
| 2018 Q3 | -3.04 Million USD | -58.69% |
| 2018 Q1 | -3.19 Million USD | 36.23% |
| 2017 FY | -12.21 Million USD | -46.62% |
| 2017 Q4 | -5 Million USD | -51.0% |
| 2017 Q3 | -3.31 Million USD | 47.42% |
| 2017 Q1 | 2.41 Million USD | -61.57% |
| 2017 Q2 | -6.3 Million USD | -361.23% |
| 2016 Q2 | -2.33 Million USD | 51.23% |
| 2016 Q1 | -4.78 Million USD | -209.14% |
| 2016 Q4 | 6.28 Million USD | 183.82% |
| 2016 FY | -8.33 Million USD | 26.63% |
| 2016 Q3 | -7.49 Million USD | -221.04% |
| 2015 Q4 | 4.38 Million USD | 189.58% |
| 2015 FY | -11.35 Million USD | 29.35% |
| 2015 Q1 | -3.86 Million USD | 48.21% |
| 2015 Q2 | -6.97 Million USD | -80.4% |
| 2015 Q3 | -4.89 Million USD | 29.85% |
| 2014 FY | -16.07 Million USD | -252.09% |
| 2014 Q3 | -4.33 Million USD | -63.13% |
| 2014 Q4 | -7.46 Million USD | -72.23% |
| 2014 Q2 | -2.65 Million USD | -64.89% |
| 2014 Q1 | -1.61 Million USD | 56.03% |
| 2013 Q3 | -2.14 Million USD | -142.47% |
| 2013 Q1 | 2.12 Million USD | 108.93% |
| 2013 Q2 | -883 Thousand USD | -141.53% |
| 2013 Q4 | -3.66 Million USD | -71.23% |
| 2013 FY | -4.56 Million USD | 82.12% |
| 2012 Q2 | -439 Thousand USD | -61.4% |
| 2012 Q1 | -272 Thousand USD | 97.35% |
| 2012 Q4 | -23.79 Million USD | -2235.23% |
| 2012 FY | -25.52 Million USD | -114.26% |
| 2012 Q3 | -1.01 Million USD | -132.12% |
| 2011 Q3 | -202 Thousand USD | 77.43% |
| 2011 Q2 | -895 Thousand USD | -62.73% |
| 2011 FY | -11.91 Million USD | -74.85% |
| 2011 Q4 | -10.26 Million USD | -4982.18% |
| 2011 Q1 | -550 Thousand USD | 78.44% |
| 2010 Q4 | -2.55 Million USD | -52.39% |
| 2010 Q1 | -1.69 Million USD | 90.79% |
| 2010 FY | -6.81 Million USD | 79.7% |
| 2010 Q2 | -890 Thousand USD | 47.62% |
| 2010 Q3 | -1.67 Million USD | -88.09% |
| 2009 Q1 | -5.71 Million USD | 66.22% |
| 2009 Q2 | -4.83 Million USD | 15.4% |
| 2009 FY | -33.56 Million USD | 2.61% |
| 2009 Q3 | -4.56 Million USD | 5.65% |
| 2009 Q4 | -18.44 Million USD | -304.38% |
| 2008 Q1 | -1.06 Million USD | 30.22% |
| 2008 Q4 | -16.92 Million USD | -87.92% |
| 2008 FY | -34.46 Million USD | -245.51% |
| 2008 Q3 | -9 Million USD | -20.42% |
| 2008 Q2 | -7.47 Million USD | -605.38% |
| 2007 Q2 | -2.49 Million USD | -31.35% |
| 2007 Q1 | -1.9 Million USD | -139.36% |
| 2007 FY | -9.97 Million USD | -184.46% |
| 2007 Q4 | -1.51 Million USD | 62.56% |
| 2007 Q3 | -4.05 Million USD | -62.47% |
| 2006 Q3 | 463 Thousand USD | -48.27% |
| 2006 Q4 | 4.83 Million USD | 943.2% |
| 2006 Q2 | 895 Thousand USD | -84.08% |
| 2006 Q1 | 5.62 Million USD | 128.5% |
| 2006 FY | 11.8 Million USD | 160.7% |
| 2005 Q1 | -62 Thousand USD | -101.33% |
| 2005 Q2 | 4.51 Million USD | 7379.03% |
| 2005 Q3 | -4.18 Million USD | -192.71% |
| 2005 Q4 | -19.72 Million USD | -371.37% |
| 2005 FY | -19.45 Million USD | -192.06% |
| 2004 Q1 | 5.97 Million USD | 33.19% |
| 2004 Q3 | 5.46 Million USD | 8.41% |
| 2004 FY | 21.13 Million USD | 72.39% |
| 2004 Q4 | 4.64 Million USD | -15.0% |
| 2004 Q2 | 5.04 Million USD | -15.6% |
| 2003 FY | 12.25 Million USD | 139.85% |
| 2003 Q2 | 2.81 Million USD | 261.44% |
| 2003 Q4 | 4.48 Million USD | 7.27% |
| 2003 Q3 | 4.18 Million USD | 48.72% |
| 2003 Q1 | 778 Thousand USD | 115.59% |
| 2002 Q4 | -4.99 Million USD | 65.14% |
| 2002 Q1 | -2.26 Million USD | -127.38% |
| 2002 Q2 | -9.19 Million USD | -305.43% |
| 2002 Q3 | -14.31 Million USD | -55.74% |
| 2002 FY | -30.76 Million USD | -584.12% |
| 2001 Q2 | 4.4 Million USD | -59.72% |
| 2001 Q4 | 8.27 Million USD | 147.98% |
| 2001 Q1 | 10.92 Million USD | 0.56% |
| 2001 Q3 | -17.25 Million USD | -492.0% |
| 2001 FY | 6.35 Million USD | -76.49% |
| 2000 FY | 27.02 Million USD | 159.88% |
| 2000 Q4 | 10.86 Million USD | 90.39% |
| 2000 Q3 | 5.7 Million USD | 17.97% |
| 2000 Q2 | 4.83 Million USD | -13.81% |
| 2000 Q1 | 5.61 Million USD | 93.58% |
| 1999 Q1 | 3.3 Million USD | 120.0% |
| 1999 Q2 | 2 Million USD | -39.39% |
| 1999 Q3 | 2.2 Million USD | 10.0% |
| 1999 FY | 10.4 Million USD | 9.47% |
| 1999 Q4 | 2.9 Million USD | 31.82% |
| 1998 Q2 | 1.6 Million USD | -68.0% |
| 1998 FY | 9.5 Million USD | 326.19% |
| 1998 Q3 | 1.5 Million USD | -6.25% |
| 1998 Q4 | 1.5 Million USD | 0.0% |
| 1998 Q1 | 5 Million USD | 1150.0% |
| 1997 Q4 | 400 Thousand USD | -20.0% |
| 1997 Q2 | 500 Thousand USD | 108.93% |
| 1997 Q1 | -5.6 Million USD | 0.0% |
| 1997 FY | -4.2 Million USD | 0.0% |
| 1997 Q3 | 500 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.41 Million USD | 156.879% |
| Arrayit Corporation | -3.31 Million USD | 124.189% |
| Atlantic International Corp. | -5.62 Million USD | 114.251% |
| Biocept, Inc. | -32.08 Million USD | 102.499% |
| Bioqual, Inc. | 483.48 Thousand USD | -65.88% |
| CardioGenics Holdings Inc | -1.91 Million USD | 141.851% |
| DermTech, Inc. | -100.88 Million USD | 100.795% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion USD | 99.96% |
| HTG Molecular Diagnostics, Inc. | -21.59 Million USD | 103.714% |
| iMD Companies, Inc. | -200.63 Thousand USD | 499.729% |
| IDenta Corp. | 14.64 Thousand USD | -5376.646% |
| Integrative Health Technologies, Inc. | 38.68 Thousand USD | -1972.941% |
| InVitro International | 1553.00 USD | -51541.983% |
| Lumos Diagnostics Holdings Limited | -8.59 Million USD | 109.334% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | 1480.094% |
| Medical Imaging Corp. | -3.02 Million USD | 126.53% |
| NovelStem International Corp. | -4.18 Million USD | 119.153% |
| Optigenex Inc. | -2.89 Million USD | 127.677% |
| PharmChem, Inc. | 845.1 Thousand USD | 5.1% |
| Proteome Sciences plc | -2.44 Million USD | 132.828% |
| Response Genetics, Inc | -20.18 Million USD | 103.973% |
| Rennova Health, Inc. | -3.29 Million USD | 124.354% |
| RushNet, Inc. | -607.02 Thousand USD | 232.119% |
| ScreenPro Security Inc. | -2.24 Million USD | 135.664% |
| Stella Diagnostics Inc. | -5.7 Million USD | 114.052% |
| StageZero Life Sciences Ltd. | -11.41 Million USD | 107.026% |
| Todos Medical Ltd. | -24.99 Million USD | 103.209% |